Company profilePharmaceutical#24 of 1,318 in Pakistan2 DRAP alerts

MASS PHARMA (PRIVATE) LIMITED

Pharmaceutical company · 331 brands · 317 molecules

Ranked #10 of 70 companies in Cardiac Care

331 registered products 63 pharmaceutical brands 317 distinct molecules 2 DRAP alerts

Company overview

331
registered products
63
pharmaceutical brands
317
distinct molecules
12
therapeutic classes
2
DRAP alerts

MASS PHARMA (PRIVATE) LIMITED is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 331 product registrations across 317 distinct molecules. It is the 24th largest registrant in Pakistan by product count, and ranks 10th of 70 in Cardiac Care. Its portfolio is concentrated in Cardiac Care and Anti-Infectives. DRAP has issued 2 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by MASS

193 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

118
ceilings with an approval date
6
not revised in 2+ years
2024
oldest approval year
20246
2025108
20264
Longest without revision

Top molecules by brand count

Nutritional Supplement / Multivitamin31 brands
Betamethasone11 brands
Clotrimazole7 brands
Amlodipine6 brands
Cephalexin5 brands
Amikacin5 brands
Bupropion5 brands
Nifedipine5 brands
Terbinafine5 brands

Therapeutic classes

Cardiac Care · 10Anti-Infectives · 9Other Beta-Lactam, Cephalosporins & Penems · 6Skin Conditions · 5Angiotensin-Ii Antagonists, Combinations · 5Corticosteroid Combinations, Topical · 4Calcium Channel Blockers · 4Quinolone Antibacterials · 3Antiinflammatory And Antirheumatic Products · 3Antithrombotic Agents · 2Neuro · 2Multivitamin, Combinations · 2

Conditions treated

Hypertension · 6General Infections · 4Fungal Infection · 4Eczema/Psoriasis/Dermatitis · 3High Cholestrol · 2Ulcer/Reflux/Flatulence/Acidity · 2Pain Killers · 2Alzheimer`S · 1Heart Failure · 1Anaemia · 1Acne/Oral · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official212 products · Rs 39.36 – Rs 20,352.17
DVAGO41 products · Rs 58.94 – Rs 850
Servaid49 products · Rs 72 – Rs 2,240
Median across source: Rs 280

Regulatory record

2 alerts in the DRAP feed we track.

13. Rapid Alert – SPURIOUS TABLET D-GEST DYDROGESTERONE 10 mg) (BATCH NO. DGH007)
2026-03-11
Rapid Alert: CRACKDOWN AGAINST FALSIFIED PRODUCT
2025-01-16

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

NEUTRO PHARMA (PVT) LTD. holds 90 molecules not in this portfolio
AcetylcysteineAcyclovirAlbendazoleAnastrazoleAnastrozoleAntimony
Wilshire Laboratories (Private) Limited holds 90 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmoxicillinAmoxycillinAmoxycillin Base
BIO LABS (PVT) LTD. holds 86 molecules not in this portfolio
AprepitantAremetherArtesunateAscorbic AcidAzithromycin 250MgBetamethasone 0.1%

Get the full profile for MASS

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.